Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & Administrative
Others
Ratios

Cullinan Therapeutics (CGEM) Other Non Operating Income (2020 - 2023)

Cullinan Therapeutics (CGEM) has 4 years of Other Non Operating Income data on record, last reported at -$117000.0 in Q4 2023.

  • For Q4 2023, Other Non Operating Income changed N/A year-over-year to -$117000.0; the TTM value through Dec 2023 reached $239000.0, changed N/A, while the annual FY2024 figure was -$199000.0, 183.26% down from the prior year.
  • Other Non Operating Income reached -$117000.0 in Q4 2023 per CGEM's latest filing, down from $180000.0 in the prior quarter.
  • Across five years, Other Non Operating Income topped out at $180000.0 in Q3 2023 and bottomed at -$241000.0 in Q2 2022.
  • Average Other Non Operating Income over 4 years is -$1909.1, with a median of -$2000.0 recorded in 2021.
  • Peak YoY movement for Other Non Operating Income: soared 133.33% in 2021, then tumbled 2912.5% in 2022.
  • A 4-year view of Other Non Operating Income shows it stood at -$12000.0 in 2020, then skyrocketed by 133.33% to $4000.0 in 2021, then plummeted by 6125.0% to -$241000.0 in 2022, then skyrocketed by 51.45% to -$117000.0 in 2023.
  • Per Business Quant database, its latest 3 readings for Other Non Operating Income were -$117000.0 in Q4 2023, $180000.0 in Q3 2023, and $69000.0 in Q2 2023.